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Telemedicine-based proactive
patient management during
positive airway pressure therapy
Impact on therapy termination rate
Introduction
Continuous positive airway pressure
(CPAP) is the most eﬀective treatment
for obstructive sleep apnoea (OSA) and
is mandated by current guidelines [1].
However, the beneﬁts of treatment can-
not be realised if patients do not adhere
to prescribed therapy.
A number of diﬀerent approaches to
improve compliance with CPAP ther-
apy have been assessed in clinical tri-
als, including patient education [2–5],
peer support [6, 7], behavioural inter-
ventions [3, 4], clinical support [8] and
choice of equipment [9–12]. In addi-
tion, features of the healthcare system
and service/treatment delivery can have
an impact on adherence [13]. Despite
this, health stakeholders have not tradi-
tionally focussed on addressing adher-
ence issues, and there are relatively few
data on interventions to improve adher-
ence,whichinturncould improvepatient
outcomes [13].
Regular follow-up by clinicians and
objective assessment of device data have
been suggested to be essential in facilitat-
ing good compliance with CPAP therapy
for OSA [14]. However, current man-
agement of CPAP compliance is reactive.
Patients who are experiencing challenges
or diﬃculties during CPAP therapy have
to contact their healthcare provider to re-
quest assistance. Alternatively, lessmoti-
vated patients might just stop using ther-
apy altogether if there is a problem, or if
they perceive there to be a problem.
Telemedicine is a term used to
describe the use of information and
communications technology to deliver
healthcare at a distance [15]. It also oﬀers
the opportunity to provide quality care
without dramatically escalating health-
care costs [16]. It is especially suited to
the management of chronic diseases that
require long-term monitoring to ensure
successful therapy [17]. Having remote
access to CPAP therapy data creates an
opportunity for healthcare professionals
to intervene proactively and provide ap-
propriate support to individual patients
with the aim of having them continue to
use PAP therapy. Remote data are useful
for tracking CPAP adherence and can
also provide information on mask leak
and residual apnoea–hypopnoea index
(AHI), but there are few data on how use
of these systems impacts on outcomes
in OSA patients [18].
This study used data from a large Ger-
manhomecare provider to investigate the
impact of a proactive patient manage-
ment programme supported by remote
access toPAPtherapydataon therapy ter-
mination compared with standard care.
Methods
Study data were obtained from ResMed
Germany Healthcare, a German home-
care provider. German data protection
law allows for the use of such data,
if anonymised, for scientiﬁc purposes.
Therefore, patient informed consent was
not necessary in this study.
Subjects
Patients who started PAP therapy for the
ﬁrst time between 1 September 2009 and
30 April 2014 and were being treated
with CPAP, automatic continuous posi-
tive airway pressure (APAP), bilevel PAP
or adaptive servo-ventilation (ASV) de-
vices, administered via a nasal mask,
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Male, n (%) 2543 (75) 2527 (74) 0.680
Age, years 59 ± 13 59 ± 13 0.254
Age group, n (%)
<30 years 46 (1) 44 (1) 0.920
30–40 years 210 (6) 215 (6) 0.840
40–50 years 601 (18) 608 (18) 0.850
50–60 years 963 (28) 962 (28) 1.000
60–70 years 816 (24) 800 (24) 0.670
70–80 years 670 (20) 676 (20) 0.880
>80 years 95 (3) 96 (3) 1.000
First mask, n (%)
Nasal 1653 (49) 1659 (49) 0.900
Nasal pillows 462 (14) 451 (13) 0.720
Full face 1286 (38) 1291 (38) 0.920
First device, n (%)
CPAP 1283 (38) 1272 (37) 0.800
APAP 1834 (54) 1855 (55) 0.630
ASV 158 (5) 157 (5) 1.000
Bilevel 126 (4) 117 (3) 0.600
Insurance, n (%)
Public 2902 (85) 2904 (85) 0.970
Private 499 (15) 497 (15) 0.970
*Pairwise testing was performed, level of significance p <0.05
Values are mean ± standard deviation, or number of patients (%)
APAP automatic continuous positive airway pressure, ASV adaptive servo-ventilation, Bilevel bilevel
positive airway pressure, CPAP continuous positive airway pressure, PAP positive airway pressure
Table 2 Therapy termination rates at 1 year









Overall 373/3401 (11.0) 185/3401 (5.4) 50.4 <0.001
Male 262/2543 (10.3) 130/2527 (5.1) 50.1 <0.001
Female 111/858 (12.9) 55/874 (6.3) 51.4 <0.001
APAP/CPAP 350/3117 (11.2) 177/3127 (5.7) 49.6 <0.001
ASV/Bilevel 23/284 (8.1) 8/274 (2.9) 63.9 0.011
Public 335/2902 (11.5) 163/2904 (5.6) 51.3 <0.001
Private 38/499 (7.6) 22/497 (4.4) 42.1 0.034
APAP automatic continuous positive airway pressure, ASV adaptive servo-ventilation, Bilevel bilevel
positive airway pressure, CPAP continuous positive airway pressure
nasal pillows or full face mask interface,
were eligible for inclusion in this analysis.
Patients who had started PAP ther-
apy ≥1 year previously were included.
Those who were managed using a proac-
tive, telemedicine-based strategy were
matched with PAP users managed using
standard care. Patients were excluded
from the analysis if they had terminated
PAP therapy for a reason that was not
related to PAP compliance (e. g. their
insurer refused to cover PAP therapy,
patient death, transfer to ventilation de-
vice). The proactive and standard care
cohorts were matched for gender, insur-
ance (public versus private), age (10-year
bands), ﬁrst device used (CPAP, APAP,
bilevel PAP or ASV), therapy start date,
initial interface (nasal mask, nasal pil-
lows or full face mask) and introduction
to device and interface (in sleep labora-
tory, at home by the homecare provider
or at the homecare provider’s service
centre).
Patient management
Standard care for each patient varied de-
pending on their health insurance, but
generallyincludedpolygraphyafterabout
6 months and when clinically necessary
thereafter, and or patient contact with
questions about device usage. If issues
arose during PAP therapy the patient
was advised to contact his/her healthcare
provider, sleep laboratory and/or treating
physician. Depending on their insurer,
standardcarepatientsmightbe contacted
at 6 months to provide device usage data.
The proactive management strat-
egy was facilitated by data obtained
via AirView™, a cloud-based remote
monitoring system that connects wire-
lessly with the PAP therapy devices
used by ResMed Germany Healthcare.
If AirView™ data showed that compli-
ance during the ﬁrst 2 weeks of PAP
therapy did not meet the required level
(average <4 h/day), patients received
a telephone call from the homecare
provider. For the period from 2 weeks
to 6 months, average usage was checked
every 14 days and patients were called
again each time continued periods of no
or low (<4 h/day) usage were identiﬁed
from AirView™ data. From 6 months of
therapy onwards, patients were notiﬁed
via telephone call or letter if AirView™
data showed that PAP device usage
dropped signiﬁcantly or did not reach
the required threshold (based on the
insurance-speciﬁed usage criteria for
reimbursement [approximate average of
4 h/night]). When contacted, patients
were proactively provided with detailed
information on use of their PAP therapy
device and management of side eﬀects
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Telemedicine-based proactive patientmanagement during positive airway pressure therapy. Impact
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Abstract
Background. Adherence to positive airway
pressure (PAP) therapy is essential for the
beneﬁts of therapy to be realised. Telemedi-
cine-based strategies provide a new option
for enhancedmonitoring and intervention to
promote adherence during PAP. This study
investigated the impact of telemedicine-
based proactive patient management on PAP
therapy termination rates versus standard
care.
Methods. Observational data were obtained
from ResMed Germany Healthcare, a German
homecare provider. Patients were undergoing
routine homecare using either a standard
or proactive management strategy. The
proactive strategy used data from AirView™,
a cloud-based remote monitoring system,
to prompt patient contact and information
sharing/education. Patients receiving their
ﬁrst PAP therapy were included and analysed
in matched pairs.
Results. In all, 3401 patients were included
in each group. In the ﬁrst year of PAP
therapy, overall therapy termination rate
was signiﬁcantly lower (5.4% vs 11.0%; p <
0.001) and time to therapy termination
was signiﬁcantly longer (348 ± 58 vs 337 ±
76 days; p < 0.05) in the proactive versus
standard care group. Cox proportional hazard
analysis revealed a signiﬁcantly reduced risk
of PAP termination in the proactive versus
the standard care group (hazard ratio 0.48,
95% conﬁdence interval 0.4–0.57). Findings
were consistent in subanalyses according to
gender, type of device and insurance status,
and in patients aged ≥40 years. However,
in the subgroup of patients aged younger
than 40 years, the risk of PAP terminationwas
similar in the proactive and standard groups.
Conclusion. A telemedicine-basedproactive
management strategy compared with
standard care of PAP patients was associated
with a lower long-term therapy termination
rate.
Keywords
Monitoring, ambulatory · Health behavior ·
Patient adherence · Obstructive sleep apnea ·
Patient compliance
Telemedizinbasierte proaktive Versorgung von Patienten während der Positivdrucktherapie.
Auswirkungen auf die Abbruchrate
Zusammenfassung
Hintergrund. Eine ausreichende Therapiead-
härenz ist erforderlich, um das therapeutische
Potenzial einer Positivdrucktherapie (PAP)
auszuschöpfen. Telemedizinbasierte
Strategien ermöglichen durch Therapiemo-
nitoring proaktive individuelle und zeitnahe
Interventionen, um die PAP-Adhärenz zu
steigern. Diese Studie untersuchte den
Einﬂuss der telemedizinbasiertenproaktiven
Versorgung von Patientenmit Schlafapnoe
auf die Abbruchrate der PAP-Therapie.
Methoden. Beobachtungsdaten wurden
durch den Deutschen Homecare Provider
ResMed Healthcare bereitgestellt. Im Rahmen
eines Fall-Kontroll-Designs wurden Patienten,
die erstmalig auf eine PAP-Therapie eingestellt
wurden, mit PAP-Standardversorgung und
proaktiver PAP-Versorgung verglichen. Die
proaktive PAP-Versorgung erfolgte mit Hilfe
der AirView™-Technologie, einem Cloud-
basierten automatisiertenMonitoringsystem,
das bei Therapieproblemen einen zeitnahen
proaktiven Patientenkontakt und Informati-
onsaustausch bzw. eine Patientenschulung
einleiten kann.
Ergebnisse. In beide Gruppen wurden jeweils
3401 Patienten eingeschlossen. Innerhalb des
ersten Jahres nach der Einstellung auf eine
PAP-Therapiewar in der Gruppemit proaktiver
PAP-Versorgung im Vergleich zu einer PAP-
Standardversorgung die Abbruchrate der
PAP-Therapie signiﬁkant niedriger (5,4 % vs.
11,0%; p < 0,001) und die durchschnittliche
Zeit bis zum Therapieabbruch signiﬁkant
länger (348 ± 58 vs. 337 ± 76 Tage; p <
0,05). Diese Verbesserung war unabhängig
von Geschlecht, Gerätetyp und Art der
Krankenversicherung sowie bei Patienten
im Alter von >40 Jahren nachweisbar. In der
Gruppe der Patientenunter 40 Jahrenwar kein
Vorteil einer proaktiven Strategie nachweisbar.
Schlussfolgerung. Ein telemedizinbasiertes
proaktives PAP-Versorgungsmodell ist mit
einer signiﬁkant geringeren Abbruchrate als
bei einer konventionellen PAP-Versorgung
assoziiert.
Schlüsselwörter
Ambulantes Monitoring · Gesundheitsver-
halten · Patientenadhärenz · Obstruktive
Schlafapnoe · Patientencompliance
Assessments
Patient characteristics, therapy termina-
tion rates and time to therapy termina-
tion were calculated for the standard care
and proactive strategy groups based on
data extracted from patient records held
by ResMed Germany Healthcare, a Ger-
man homecare provider. Therapy termi-
nation was then described as compliance
related if it occurred as the result of pa-
tient decision or behavior, was related to
complaints by the patient, or was related
to the PAP interface (i. e. not accepting
or tolerating PAP therapy). Termina-
tions that were not compliance related
occurred when a patient was lost to fol-
low-up, transferredtoaventilationdevice
or died, or were related to insurance cov-
erage issues or patient transfer to another
homecare provider.
Data analysis
Descriptive statistics are shown as abso-
lute and relative frequency or mean ±
standard deviation (SD), as appropriate.
Numerical diﬀerences between groups
were analysed using t-tests because the
sample size allows for this approxima-
tion. For categorical data, diﬀerences in
proportions were analysed using Z-tests.
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Observation time (days)N at risk
3401 3292 3150 2982 2906












Matchingwasused toeliminate the in-
ﬂuence of unequal distributions of risk
factors on diﬀerences in compliance be-
tween the proactive care and standard
care groups. Propensity score matching
was conducted based on the following
factors: gender, insurance, age (10-year
bands), ﬁrst device, therapy start date,
ﬁrst mask and therapy set up. Time to
therapy termination was analyzed using
Coxproportionalhazardsregressionwith
standard vs. proactive care included as
an explanatory factor. The results for
marginal times to termination were vi-
sualized using Kaplan–Meier plots. A p-
value of<0.05was considered statistically
signiﬁcant. All statistical analyses were
performed using IBM SPSS Statistics 22
and R version 3.0.2.
Results
A total of 3401 patients who were man-
aged using the proactive strategy and
3401 matched patients receiving stan-
dard care were included in the analy-
sis. There were no signiﬁcant diﬀerences
between the matched groups at baseline
(. Table 1).
PAP termination
The overall therapy termination rate
was more than halved by the proactive
strategy compared with standard care
(5.4% vs 11.0%, respectively) (. Table 2).
Mean time to therapy termination in
the ﬁrst year was 348 ± 58 days in
the proactive strategy group compared
with 337 ± 76 days in the standard care
group. Cox proportional hazard analysis
revealed a signiﬁcantly reduced risk of
PAP termination in the proactive versus
the standard care group (hazard ratio
0.48, 95% conﬁdence interval 0.4–0.54)
(. Fig. 1).
Subanalyses according to potential
modiﬁers
Therapy termination rates with the stan-
dard andproactive strategieswere similar
in males and females (. Table 2), and
for both genders the proactive strategy
signiﬁcantly reduced the risk of therapy
termination compared with standard
management. The risk of therapy ter-
mination was signiﬁcantly reduced by
the proactive strategy versus standard
care in patients aged ≥40–69 years and
≥70 years, but there was no signiﬁcant
diﬀerence between the two manage-
ment strategies in younger patients (age
<40 years) (. Fig. 2). Therapy termi-
nation risk reduction with proactive
management was the greatest (63.9%) in
patients receiving bilevel PAP or ASV,
although the risk of therapy termination
did not diﬀer signiﬁcantly based on the
type of device used (. Table 2). The over-
all signiﬁcant beneﬁt of the proactive
strategy compared with standard care
on therapy termination was the same in
patients whose ﬁrst device was APAP or
CPAP, or bilevel or ASV. The proactive
strategy was also eﬀective in reducing
the therapy termination rate in patients
with either public or private insurance,
with a slightly greater beneﬁcial eﬀect in
those with public insurance.
Discussion
The results of this study showed that
a telemedicine-based proactive strategy
for the management of patients receiving
PAP therapy reduced the rate of ther-
apy termination over time, irrespective
of gender, device used and the type of
insurance. The ﬁnding that the proac-
tive strategy was eﬀective irrespective of
the type of PAP device used might sug-
gest that therapy acceptability (e. g. in-
terface comfort) may play a bigger role
than the type of device being used. Inter-
estingly, the positive eﬀects of proactive
care were seen in all age groups except
those aged<40years. Onepossible expla-
nation for this may be that the youngest
patients aremore comfortable with using
information technology to better inform
themselves about their condition.
To the best of our knowledge, this
study is the ﬁrst to investigate the impact
of a telemedicine-based strategy on long-
term continuation of PAP therapy. The
main outcome measure in many previ-
ous studies has been compliance in terms
of hours of device usage per night, and
there is a lack of data on therapy ter-
mination rates. The majority of these
studies have focussed only on CPAP in
patients with OSA, used a variety of dif-
ferent telemedicine-based strategies, and
reported inconsistent results. In addi-
tion, themajority were small, single-cen-
tre and/or short-term studies [19–24].
Interface problems and side eﬀects are
the most common causes of CPAP intol-
eranceandan importantpotential beneﬁt
of telemedicine-based strategies is early
identiﬁcation of these issues and the im-
plementationofstrategies toresolve them
in a timely fashion. Other beneﬁts of
telemonitoring strategies have been re-
ported, such as reduced labour time for
healthcare staﬀ, allowing the same levels
of adherence and eﬃcacy to be achieved
with fewer staﬀ resources [17, 25]. This is
important in the contextof aprojected in-
crease in the number of patients present-
ing with sleep-disordered breathing due
to the aging population and the growing
rates of comorbidities such as obesity and
diabetes that will increase demand for al-
ready stretched healthcare services. The






















HR = 1  ( 0.55 , 1.83 )
p = 0.999
Proactive vs. Standard
Observation time (days)N at risk
256 255 247 230 226
259 256 251 228 221
Standard
Proactive

















HR = 0.53  ( 0.34 , 0.81 )
p = 0.003
Proactive vs. Standard
Observation time (days)N at risk
601 586 564 534 518
608 600 591 559 553
Standard
Proactive

















HR = 0.43  ( 0.3 , 0.62 )
p < 0.001
Proactive vs. Standard
Observation time (days)N at risk
963 935 894 854 837
962 954 937 899 889
Standard
Proactive

















HR = 0.51  ( 0.35 , 0.76 )
p < 0.001
Proactive vs. Standard
Observation time (days)N at risk
816 795 768 732 718
800 787 776 736 726
Standard
Proactive

















HR = 0.39  ( 0.27 , 0.57 )
p < 0.001
Proactive vs. Standard
Observation time (days)N at risk
670 635 602 561 541
676 660 645 621 614
Standard
Proactive
















StandardHR = 0.34  ( 0.16 , 0.74 )
p = 0.006
Proactive vs. Standard
Observation time (days)N at risk
95 86 75 71 66
96 91 88 82 80
Standard
Proactive
Fig. 28 Kaplan–Meier plot showing risk of therapy termination inpositive airwaypressure usersmanagedusing a proactive
strategyversus standardcarebasedonpatientage (aAge<40years.bAge40–49years. cAge50–59years. dAge60–69years.
eAge 70–79 years. fAge≥80 years)
patient-focussed, proactive and intensive
management of patients using PAP ther-
apy facilitates the management of large
patient populations, as well as signiﬁ-
cantly improving therapy continuation
rates and usage. Telemedicine also ap-
pears to be a cost eﬀective strategy for
managing CPAP treatment in patients
with OSA [16].
Improved patient engagement is an-
otherpotential advantageof telemedicine
strategies, which in turn could contribute
to additional gains in terms of PAP ad-
herence and outcomes. The positive im-
pact of patient involvement in therapy
was highlighted in a recent study which
showed that providingpatientswithweb-
based access to their personal PAP usage
data increased device usage in the ﬁrst
week of therapy and over 3 months of
follow-up comparedwith usual care [26].
AccordingtotheWorldHealthOrgan-
isation(WHO), it is important thathealth
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systems evolve to meet new challenges
[13]. The introduction of new technolo-
gies, such as telemedicine, is one way in
which healthcare systems and providers
can advance patient care. In the case
of PAP therapy this could contribute to
better adherence and improved patient
outcomes. WHO has also recognised
that interventions targeted at improv-
ing adherence should provide a signif-
icant positive return on investment via
prevention of adverse health outcomes,
and that there are also economic bene-
ﬁts associated with improved quality of
life, including reductions in indirect costs
and increased productivity [13]. In the
context of CPAP therapy for OSA, the
importance of increasing adherence has
also been recognised by a Cochrane re-
view that emphasised the need for new
strategies to promote CPAP compliance
[27].
One of the main limitations of this
analysis is the lack of speciﬁc data on
device usage in the standard care group.
Thus, we report therapy termination
rates rather than device usage hours,
which made comparison with existing
data more diﬃcult. However, it could be
argued that therapy termination is the
most important endpoint to assess be-
cause once a patient stops therapy getting
them to restart is likely to be diﬃcult. In
contrast, reduced usage provides a cue
for intervention, and there is always the
possibility that hours of device use will
increase. Another potential limitation is
that the ability to accurately determine
therapy termination is diﬀerent in the
two groups – it is very obvious when
patients in the proactive strategy group
stop PAP therapy based on device data
received, but therapy termination might
be less obvious in the standard care
group for whom the requirement for
a homecare provider visit may be the
only indicator of therapy problems or
termination. Interrogation of big data
allows inclusion of a very large popula-
tion of patients treated in routine clinical
practice. However, databases created for
administrative, rather than scientiﬁc,
purposes do not include a full set of
clinical data. In the current analysis, this
means that we had no data on clinical
features, insomnia and other factors that
might have inﬂuenced the outcomes
under study. Furthermore, these are
observational data and therefore do not
provide proof for a causative relation-
ship between the intervention (proactive
care) and the outcome (reduced therapy
termination). Data from randomised
clinical trials are needed to more clearly
elucidate the eﬀects of a telemedicine-
based proactive management strategy
on PAP therapy termination rates. In
addition, future research should further
investigate the potential of telemonitor-
ing-guided proactive care on additional
endpoints, including device usage, re-
source use and healthcare professional
time requirements.
Conclusion
This analysis of a large population of PAP
therapy users in Germany showed that
the long-termrate of therapy termination
was signiﬁcantly lower in patients man-
aged using a telemedicine-based proac-
tivemanagement strategy comparedwith
standard care. This association was ob-
served in both men and women, across
a wide range of patient ages, for all PAP
devices and in patients with public or
private insurance. Implementation of
telemedicine-based strategies has the po-
tential to improve adherence and patient
outcomes and may allow more eﬃcient
allocation of scarce healthcare resources.
Randomized, controlled clinical trials are
needed to further assess both therapy ter-
mination rates and device usage, which
would complement our large data set
from routine clinical practice.
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